Expression of bcl-2, p53, and p21 in benign and malignant prostatic tissue before and after radiation therapy

Christiane Rakozy, David Grignon, Fazlul H. Sarkar, Wael A. Sakr, Peter Littrup, Jeffrey Forman

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Abnormalities in genes of the apoptotic pathway might contribute to survival in prostatic cancer (PCa) cells after radiation therapy (RT). We investigated the immunohistochemical expression of the products of the p53, p21(WAF1), and bcl-2 genes in pre-RT and post-RT biopsy specimens from 38 patients with locally advanced PCa. All of the 38 patients underwent a uniform protocol of RT with or without neoadjuvant hormonal therapy. Immunohistochemical staining for expression of the products of the p53, p21(WAF1), and bcl-2 genes was performed on material from pre-RT and post-RT specimens. Sufficient tissue for analysis was available from 25 of the pre- RT and 38 of the post-RT biopsy specimens. In benign prostatic epithelium, RT resulted in expression of p53 (2 [8%] of 25 pre-RT specimens vs. 15 [71%] of 21 post-RT specimens; P <.001) and increased expression of bcl-2 (1 [5%] of 18 pre-RT vs. 18 [86%] of 21 post-RT; P <.001). There was no change in the expression of p21(WAF1) (1 [4.5%] of 22 pre-RT vs. 4 [17%] of 23 post-RT; P = NS). Post-RT specimens were positive for PCa in 24 (63%) of 38 cases. In the PCa tissue, p53 expression was seen in 10 (42%) of 24 pre-RT and 12 (63%) of 19 post-RT samples (P = NS). A significant upregulation of p53 was seen in the subgroup of patients who did not receive neoadjuvant hormonal therapy (9 [82%] of 11 vs. 3 [38%] of 8; P = .05). No significant change in p21(WAF1) (5 [21%] of 24 vs. 5 [33%] of 15; P = NS), or bcl-2 (4 [18%] of 22 vs. 3 [21%] of 14; P = NS) expression was detected. There was no significant correlation between immunohistochemical expression of apoptosis-related markers and treatment failure. We concluded that RT induced upregulation of the bcl-2 and p53 gene products in benign prostatic tissue and that this likely reflected a protective mechanism in genetically unaltered epithelium. Increased p53 expression in PCa was only seen in patients without neoadjuvant hormonal treatment, indicating that the cancer cells with abnormal p53 were at least partially protected from RT-induced cell death.

Original languageEnglish (US)
Pages (from-to)892-899
Number of pages8
JournalModern Pathology
Volume11
Issue number9
StatePublished - Sep 1998
Externally publishedYes

Fingerprint

Radiotherapy
Prostatic Neoplasms
bcl-2 Genes
Neoadjuvant Therapy
Up-Regulation
Epithelium
Biopsy
p53 Genes
Treatment Failure
Cell Death

Keywords

  • Apoptosis
  • Bcl- 2
  • Biopsy
  • Carcinoma
  • Immunohistochemistry
  • p21
  • p53
  • Prostate
  • Radiation therapy
  • Tumor suppressor genes

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Rakozy, C., Grignon, D., Sarkar, F. H., Sakr, W. A., Littrup, P., & Forman, J. (1998). Expression of bcl-2, p53, and p21 in benign and malignant prostatic tissue before and after radiation therapy. Modern Pathology, 11(9), 892-899.

Expression of bcl-2, p53, and p21 in benign and malignant prostatic tissue before and after radiation therapy. / Rakozy, Christiane; Grignon, David; Sarkar, Fazlul H.; Sakr, Wael A.; Littrup, Peter; Forman, Jeffrey.

In: Modern Pathology, Vol. 11, No. 9, 09.1998, p. 892-899.

Research output: Contribution to journalArticle

Rakozy, C, Grignon, D, Sarkar, FH, Sakr, WA, Littrup, P & Forman, J 1998, 'Expression of bcl-2, p53, and p21 in benign and malignant prostatic tissue before and after radiation therapy', Modern Pathology, vol. 11, no. 9, pp. 892-899.
Rakozy, Christiane ; Grignon, David ; Sarkar, Fazlul H. ; Sakr, Wael A. ; Littrup, Peter ; Forman, Jeffrey. / Expression of bcl-2, p53, and p21 in benign and malignant prostatic tissue before and after radiation therapy. In: Modern Pathology. 1998 ; Vol. 11, No. 9. pp. 892-899.
@article{aa6b54fdc71c4430beb416af0056c488,
title = "Expression of bcl-2, p53, and p21 in benign and malignant prostatic tissue before and after radiation therapy",
abstract = "Abnormalities in genes of the apoptotic pathway might contribute to survival in prostatic cancer (PCa) cells after radiation therapy (RT). We investigated the immunohistochemical expression of the products of the p53, p21(WAF1), and bcl-2 genes in pre-RT and post-RT biopsy specimens from 38 patients with locally advanced PCa. All of the 38 patients underwent a uniform protocol of RT with or without neoadjuvant hormonal therapy. Immunohistochemical staining for expression of the products of the p53, p21(WAF1), and bcl-2 genes was performed on material from pre-RT and post-RT specimens. Sufficient tissue for analysis was available from 25 of the pre- RT and 38 of the post-RT biopsy specimens. In benign prostatic epithelium, RT resulted in expression of p53 (2 [8{\%}] of 25 pre-RT specimens vs. 15 [71{\%}] of 21 post-RT specimens; P <.001) and increased expression of bcl-2 (1 [5{\%}] of 18 pre-RT vs. 18 [86{\%}] of 21 post-RT; P <.001). There was no change in the expression of p21(WAF1) (1 [4.5{\%}] of 22 pre-RT vs. 4 [17{\%}] of 23 post-RT; P = NS). Post-RT specimens were positive for PCa in 24 (63{\%}) of 38 cases. In the PCa tissue, p53 expression was seen in 10 (42{\%}) of 24 pre-RT and 12 (63{\%}) of 19 post-RT samples (P = NS). A significant upregulation of p53 was seen in the subgroup of patients who did not receive neoadjuvant hormonal therapy (9 [82{\%}] of 11 vs. 3 [38{\%}] of 8; P = .05). No significant change in p21(WAF1) (5 [21{\%}] of 24 vs. 5 [33{\%}] of 15; P = NS), or bcl-2 (4 [18{\%}] of 22 vs. 3 [21{\%}] of 14; P = NS) expression was detected. There was no significant correlation between immunohistochemical expression of apoptosis-related markers and treatment failure. We concluded that RT induced upregulation of the bcl-2 and p53 gene products in benign prostatic tissue and that this likely reflected a protective mechanism in genetically unaltered epithelium. Increased p53 expression in PCa was only seen in patients without neoadjuvant hormonal treatment, indicating that the cancer cells with abnormal p53 were at least partially protected from RT-induced cell death.",
keywords = "Apoptosis, Bcl- 2, Biopsy, Carcinoma, Immunohistochemistry, p21, p53, Prostate, Radiation therapy, Tumor suppressor genes",
author = "Christiane Rakozy and David Grignon and Sarkar, {Fazlul H.} and Sakr, {Wael A.} and Peter Littrup and Jeffrey Forman",
year = "1998",
month = "9",
language = "English (US)",
volume = "11",
pages = "892--899",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Expression of bcl-2, p53, and p21 in benign and malignant prostatic tissue before and after radiation therapy

AU - Rakozy, Christiane

AU - Grignon, David

AU - Sarkar, Fazlul H.

AU - Sakr, Wael A.

AU - Littrup, Peter

AU - Forman, Jeffrey

PY - 1998/9

Y1 - 1998/9

N2 - Abnormalities in genes of the apoptotic pathway might contribute to survival in prostatic cancer (PCa) cells after radiation therapy (RT). We investigated the immunohistochemical expression of the products of the p53, p21(WAF1), and bcl-2 genes in pre-RT and post-RT biopsy specimens from 38 patients with locally advanced PCa. All of the 38 patients underwent a uniform protocol of RT with or without neoadjuvant hormonal therapy. Immunohistochemical staining for expression of the products of the p53, p21(WAF1), and bcl-2 genes was performed on material from pre-RT and post-RT specimens. Sufficient tissue for analysis was available from 25 of the pre- RT and 38 of the post-RT biopsy specimens. In benign prostatic epithelium, RT resulted in expression of p53 (2 [8%] of 25 pre-RT specimens vs. 15 [71%] of 21 post-RT specimens; P <.001) and increased expression of bcl-2 (1 [5%] of 18 pre-RT vs. 18 [86%] of 21 post-RT; P <.001). There was no change in the expression of p21(WAF1) (1 [4.5%] of 22 pre-RT vs. 4 [17%] of 23 post-RT; P = NS). Post-RT specimens were positive for PCa in 24 (63%) of 38 cases. In the PCa tissue, p53 expression was seen in 10 (42%) of 24 pre-RT and 12 (63%) of 19 post-RT samples (P = NS). A significant upregulation of p53 was seen in the subgroup of patients who did not receive neoadjuvant hormonal therapy (9 [82%] of 11 vs. 3 [38%] of 8; P = .05). No significant change in p21(WAF1) (5 [21%] of 24 vs. 5 [33%] of 15; P = NS), or bcl-2 (4 [18%] of 22 vs. 3 [21%] of 14; P = NS) expression was detected. There was no significant correlation between immunohistochemical expression of apoptosis-related markers and treatment failure. We concluded that RT induced upregulation of the bcl-2 and p53 gene products in benign prostatic tissue and that this likely reflected a protective mechanism in genetically unaltered epithelium. Increased p53 expression in PCa was only seen in patients without neoadjuvant hormonal treatment, indicating that the cancer cells with abnormal p53 were at least partially protected from RT-induced cell death.

AB - Abnormalities in genes of the apoptotic pathway might contribute to survival in prostatic cancer (PCa) cells after radiation therapy (RT). We investigated the immunohistochemical expression of the products of the p53, p21(WAF1), and bcl-2 genes in pre-RT and post-RT biopsy specimens from 38 patients with locally advanced PCa. All of the 38 patients underwent a uniform protocol of RT with or without neoadjuvant hormonal therapy. Immunohistochemical staining for expression of the products of the p53, p21(WAF1), and bcl-2 genes was performed on material from pre-RT and post-RT specimens. Sufficient tissue for analysis was available from 25 of the pre- RT and 38 of the post-RT biopsy specimens. In benign prostatic epithelium, RT resulted in expression of p53 (2 [8%] of 25 pre-RT specimens vs. 15 [71%] of 21 post-RT specimens; P <.001) and increased expression of bcl-2 (1 [5%] of 18 pre-RT vs. 18 [86%] of 21 post-RT; P <.001). There was no change in the expression of p21(WAF1) (1 [4.5%] of 22 pre-RT vs. 4 [17%] of 23 post-RT; P = NS). Post-RT specimens were positive for PCa in 24 (63%) of 38 cases. In the PCa tissue, p53 expression was seen in 10 (42%) of 24 pre-RT and 12 (63%) of 19 post-RT samples (P = NS). A significant upregulation of p53 was seen in the subgroup of patients who did not receive neoadjuvant hormonal therapy (9 [82%] of 11 vs. 3 [38%] of 8; P = .05). No significant change in p21(WAF1) (5 [21%] of 24 vs. 5 [33%] of 15; P = NS), or bcl-2 (4 [18%] of 22 vs. 3 [21%] of 14; P = NS) expression was detected. There was no significant correlation between immunohistochemical expression of apoptosis-related markers and treatment failure. We concluded that RT induced upregulation of the bcl-2 and p53 gene products in benign prostatic tissue and that this likely reflected a protective mechanism in genetically unaltered epithelium. Increased p53 expression in PCa was only seen in patients without neoadjuvant hormonal treatment, indicating that the cancer cells with abnormal p53 were at least partially protected from RT-induced cell death.

KW - Apoptosis

KW - Bcl- 2

KW - Biopsy

KW - Carcinoma

KW - Immunohistochemistry

KW - p21

KW - p53

KW - Prostate

KW - Radiation therapy

KW - Tumor suppressor genes

UR - http://www.scopus.com/inward/record.url?scp=0031691437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031691437&partnerID=8YFLogxK

M3 - Article

C2 - 9758370

AN - SCOPUS:0031691437

VL - 11

SP - 892

EP - 899

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 9

ER -